Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)

Nasser K. Altorki; Zachary H. Walsh; Johannes C. Melms; Jeffery L. Port; Benjamin E. Lee; Abu Nasar; Cathy Spinelli; Lindsay Caprio; Meri Rogava; Patricia Ho; Paul J. Christos; Ashish Saxena; Olivier Elemento; Bhavneet Bhinder; Casey Ager; Amit Dipak Amin; Nicholas J. Sanfilippo; Vivek Mittal; Alain C. Borczuk; Silvia C. Formenti; Benjamin Izar; Timothy E. McGraw

doi:10.1038/s41467-023-44575-3

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)

Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. FormentiBenjamin Izar, Timothy E. McGraw

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: Nature Communications, published online 19 December 2023 In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

Original language	English (US)
Article number	225
Journal	Nature Communications
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41467-023-44575-3
State	Published - Dec 2024

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-023-44575-3

Cite this

Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., Christos, P. J., Saxena, A., Elemento, O., Bhinder, B., Ager, C., Amin, A. D., Sanfilippo, N. J., Mittal, V., Borczuk, A. C., ... McGraw, T. E. (2024). Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x). Nature Communications, 15(1), Article 225. https://doi.org/10.1038/s41467-023-44575-3

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x). / Altorki, Nasser K.; Walsh, Zachary H.; Melms, Johannes C. et al.
In: Nature Communications, Vol. 15, No. 1, 225, 12.2024.

Research output: Contribution to journal › Comment/debate › peer-review

Altorki, NK, Walsh, ZH, Melms, JC, Port, JL, Lee, BE, Nasar, A, Spinelli, C, Caprio, L, Rogava, M, Ho, P, Christos, PJ, Saxena, A, Elemento, O, Bhinder, B, Ager, C, Amin, AD, Sanfilippo, NJ, Mittal, V, Borczuk, AC, Formenti, SC, Izar, B & McGraw, TE 2024, 'Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)', Nature Communications, vol. 15, no. 1, 225. https://doi.org/10.1038/s41467-023-44575-3

Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A et al. Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x). Nature Communications. 2024 Dec;15(1):225. doi: 10.1038/s41467-023-44575-3

Altorki, Nasser K. ; Walsh, Zachary H. ; Melms, Johannes C. et al. / Author Correction : Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x). In: Nature Communications. 2024 ; Vol. 15, No. 1.

@article{835ed09944264828a07dccf0b27ca007,

title = "Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)",

abstract = "Correction to: Nature Communications, published online 19 December 2023 In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.",

author = "Altorki, {Nasser K.} and Walsh, {Zachary H.} and Melms, {Johannes C.} and Port, {Jeffery L.} and Lee, {Benjamin E.} and Abu Nasar and Cathy Spinelli and Lindsay Caprio and Meri Rogava and Patricia Ho and Christos, {Paul J.} and Ashish Saxena and Olivier Elemento and Bhavneet Bhinder and Casey Ager and Amin, {Amit Dipak} and Sanfilippo, {Nicholas J.} and Vivek Mittal and Borczuk, {Alain C.} and Formenti, {Silvia C.} and Benjamin Izar and McGraw, {Timothy E.}",

note = "Publisher Copyright: {\textcopyright} 2024, The Author(s).",

year = "2024",

month = dec,

doi = "10.1038/s41467-023-44575-3",

language = "English (US)",

volume = "15",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Author Correction

T2 - Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)

AU - Altorki, Nasser K.

AU - Walsh, Zachary H.

AU - Melms, Johannes C.

AU - Port, Jeffery L.

AU - Lee, Benjamin E.

AU - Nasar, Abu

AU - Spinelli, Cathy

AU - Caprio, Lindsay

AU - Rogava, Meri

AU - Ho, Patricia

AU - Christos, Paul J.

AU - Saxena, Ashish

AU - Elemento, Olivier

AU - Bhinder, Bhavneet

AU - Ager, Casey

AU - Amin, Amit Dipak

AU - Sanfilippo, Nicholas J.

AU - Mittal, Vivek

AU - Borczuk, Alain C.

AU - Formenti, Silvia C.

AU - Izar, Benjamin

AU - McGraw, Timothy E.

PY - 2024/12

Y1 - 2024/12

N2 - Correction to: Nature Communications, published online 19 December 2023 In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

AB - Correction to: Nature Communications, published online 19 December 2023 In this article, the author name Silvia C. Formenti was incorrectly written as Sylvia C. Formenti. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85181248747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85181248747&partnerID=8YFLogxK

U2 - 10.1038/s41467-023-44575-3

DO - 10.1038/s41467-023-44575-3

M3 - Comment/debate

C2 - 38172131

AN - SCOPUS:85181248747

SN - 2041-1723

VL - 15

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 225

ER -

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial (Nature Communications, (2023), 14, 1, (8435), 10.1038/s41467-023-44195-x)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this